New eye drops aim to tame uveitis without steroids
NCT ID NCT07285070
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This study tests NOV05, a water-free tacrolimus eye drop, in 20 adults with active non-infectious anterior uveitis. Participants receive either a high or low dose for 6 weeks. The goal is to see if it safely controls inflammation and reduces the need for steroid eye drops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tacrolimus eye drops
- What this could lead to
- If successful, this could provide a steroid-sparing option to control eye inflammation in uveitis patients.
- What could go wrong
- This is a small, early-phase proof-of-concept study with only 20 participants. The treatment may not prove effective or safe enough to advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-INFECTIOUS ANTERIOR UVEITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bascom Palmer Eye Institute
RECRUITINGMiami, Florida, 33136, United States
-
Horizon Eye & Lasik Center
RECRUITINGPhoenix, Arizona, 85004, United States
-
Massachusetts Eye Research and Surgery Institution
RECRUITINGWaltham, Massachusetts, 02451, United States
-
Metropolitan Eye Research and Surgery Institute
RECRUITINGPalisades Park, New Jersey, 07650, United States
-
Valley Retina Institute, P.A.
RECRUITINGMcAllen, Texas, 78503, United States
-
Virginia Eye Consultants
RECRUITINGNorfolk, Virginia, 23502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.